Clincosm LogoSign in Get a demo

LONGCOVIHOM: Use of Homeopathy in Patients Suffering From Long COVID-19

Sponsor
Michael Frass (Other)
Overall Status
Completed
CT.gov ID
NCT06002230
Collaborator
Sigmund Freud PrivatUniversitat (Other)
15
Enrollment
1
Location
31.1
Actual Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In some patients, coronavirus (COVID-19) can cause symptoms that last weeks or even months after the infection has gone. The aim of this study was to describe the effect of adjunctive individualized homeopathic treatment delivered to Long-COVID-19 patients with previously confirmed symptomatic SARS-CoV-2 infection.

Condition or Disease Intervention/Treatment Phase
  • Drug: Homeopathic medicines

Detailed Description

All patients had been tested positive for SARS-CoV-2 before having developed Long-COVID-19 symptoms. Several testing methods were carried out in each patient to analyze a SARS-CoV-2 infection. For a confirmed infection, at least 3 out of these 5 tests had to be positive. Tests for the orthomyxoviruses influenza A and B, human metapneumovirus (hMPV) and paramyxoviruses were negative unless stated otherwise.

The homeopathic physician treated all Long-COVID-19 patients by individualized homeopathy. Repertorization of the symptoms of the current pandemic and a search in the current homeopathic literature on COVID-19 was performed using computer program. All available homeopathic medicinal products (HMPs) could be chosen by the treating physician.

Modified MONARCH criteria were assessed post hoc by all authors. Deviations were solved by discussion in person. Clinical outcome of case reports was evaluated using the "Modified Naranjo Criteria for Homeopathy-Causal Attribution Inventory". Eight points is assumed as the limit for potential correlation between homeopathic therapy and amelioration of the symptoms or healing in chronic cases.

Study Design

Study Type:
Observational
Actual Enrollment :
15 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Use of Homeopathy in Patients Suffering From Long COVID-19 (LONGCOVIHOM): A Retrospective Case Series
Actual Study Start Date :
Jan 5, 2021
Actual Primary Completion Date :
Oct 19, 2021
Actual Study Completion Date :
Aug 10, 2023

Arms and Interventions

Arm Intervention/Treatment
Patients treated with individualized homeopathy

Patients suffering from symptoms of Long COVID-19 were treated with individualized homeopathy.

Drug: Homeopathic medicines
Globules were administered orally..
Other Names:
  • Homeopathic medicinal products

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Modified Naranjo criteria [3 days]

      10 Naranjo criteria are evaluated, eight points is assumed as the limit for potential correlation between homeopathic therapy and amelioration of the symptoms or healing in chronic cases.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    Female
    Inclusion Criteria:

    Long COVID-19 symptoms following recovery from SARS-CoV-2 infection

    Exclusion Criteria:

    Patients not signing informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sigmund Freud Private University Vienna Austria 1020

    Sponsors and Collaborators

    • Michael Frass
    • Sigmund Freud PrivatUniversitat

    Investigators

    • Study Director: Michael Frass, MD, Institute for Homeopathic Research

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Frass, Clinical professor, Medical University of Vienna
    ClinicalTrials.gov Identifier:
    NCT06002230
    Other Study ID Numbers:
    • 111
    First Posted:
    Aug 21, 2023
    Last Update Posted:
    Aug 22, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Michael Frass, Clinical professor, Medical University of Vienna
    Complementary therapy
    Homeopathy
    COVID-19
    Long-COVID-19
    SARS-CoV-2
    Additional relevant MeSH terms:
    COVID-19
    Post-Acute COVID-19 Syndrome

    Study Results

    No Results Posted as of Aug 22, 2023